Cryoport, Inc. (NASDAQ:CYRX)
| Market Cap | $964.87M+117.0% |
| Revenue (ttm) | $192.44M+1.1% |
| Net Income | -$40.18M-159.5% |
| EPS | -$0.89-176.1% |
| Shares Out | 50.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 814,779 |
| Open | $19.26 |
| Previous Close | $19.55 |
| Day's Range | $18.81 - $19.30 |
| 52-Week Range | $7.61 - $21.78 |
| Beta | 1.89 |
| Analysts | Buy |
| Price Target | $21.93(+15.12%) |
| Earnings Date | Mar 2, 2027 |
About CYRX
Cryoport, Inc. operates as a specialized service provider within the life sciences sector, delivering global temperature-controlled supply chain solutions across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Central to their offerings is Cryoportal, a proprietary cloud-based platform designed to streamline the entire logistics process. This robust system facilitates order processing, generates necessary documentation (including customs paperwork), coordinates courier services, offers real-time shipment tracking and monitoring, aids in issue resolution, and ensures adherence to regulatory compliance standards. To guarantee the integrity of sensitive materials during transit, Cryoport provides CryoPort Express Shippers, engineered to maintain the stability of biological commodities throughout their journey. Furthermore, their SmartPak Condition Monitoring System collects vital environmental data, which is then utilized to produce informative dashboards and essential validation reports for each shipment. Their product range also includes specialized containment solutions such as vacuum insulated aluminum dewars and advanced cryogenic freezer systems. Beyond transportation, the company offers extensive biological specimen management services. These encompass cryopreservation storage and ongoing maintenance, meticulous archiving, continuous monitoring, precise tracking, and efficient receipt and delivery of samples. They also manage the transport of frozen biological specimens to and from client facilities and oversee the inbound and outbound flow of these critical materials. Additionally, Cryoport extends its expertise through comprehensive logistics support and management services, alongside short-term consulting in both logistics and engineering. The company primarily caters to the biopharmaceutical, animal health, and human reproductive medicine industries. Founded in 1999, Cryoport's headquarters are situated in Brentwood, Tennessee.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
4 firms rating CYRX in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 2, 2027Earnings report
$CYRX stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of CYRX by members of U.S. Congress
| Josh GottheimerHouse / D | Sale$1.00K – $15.00K | Sep 15, 2023 |
| Gilbert Ray CisnerosHouse / D | Sale$1.00K – $15.00K | Nov 24, 2020 |
| Gilbert CisnerosHouse / D | Sale$1.00K – $15.00K | Nov 24, 2020 |
| Gilbert Ray CisnerosHouse / D | Sale$1.00K – $15.00K | Nov 23, 2020 |
| Josh GottheimerHouse / D | Sale$1.00K – $15.00K | Nov 13, 2020 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Feb 6, 2020 |
| Gilbert CisnerosHouse / D | Purchase$1.00K – $15.00K | Feb 6, 2020 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Feb 5, 2020 |
Recently reported changes in CYRX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CYRX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CYRX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
CYRX Revenue by Segment or Geography
| Segment Reporting | $50.22M | 82.78% |
| Adjusted EBITDA for reportable segments | $6.15M | 10.14% |
| Investment income | $3.03M | 4.99% |
| Cost, rent | $600.00K | 0.99% |
| Cost, stock-based compensation | $400.00K | 0.66% |
| Engineering and development, stock based compensation | $200.00K | 0.33% |
| Change in fair value of contingent consideration | $72.00K | 0.12% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New CYRX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CYRX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CYRX
| IWMiShares Russell 2000 ETF | $25.58M |
| VTIVanguard Morningstar Total Stock Market ETF | $20.77M |
| VXFVanguard Extended Market ETF | $10.00M |
| IWNiShares Russell 2000 Value ETF | $9.13M |
| DFASDimensional - US Small Cap ETF | $6.00M |
| SCHASchwab U.S. Small-Cap ETF | $5.18M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from CYRX’s recent data — informational, not investment advice
What’s Behind the Score
News check: Analyst upgrade with raised price target and positive guidance updates offset valuation concerns and insider selling activity.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| NIFE | Direxion Fallen Knives ETF | 1.50% |
| FESC | First Eagle Small Cap Equity ETF | 1.00% |
| QQQS | Invesco NASDAQ Future Gen 200 ETF | 0.73% |
| SGRW | Harbor Active Small Cap Growth ETF (SGRW) | 0.70% |
| DWAS | Invesco Dorsey Wright SmallCap Momentum ETF | 0.47% |
| SCDS | JPMorgan Fundamental Data Science Small Core ETF | 0.17% |
| EES | WisdomTree U.S. SmallCap Fund | 0.15% |
| VFMO | Vanguard U.S. Momentum Factor ETF | 0.11% |
| GSSC | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | 0.09% |
| AVSC | Avantis U.S. Small Cap Equity ETF | 0.07% |
| IWN | iShares Russell 2000 Value ETF | 0.07% |
| IQES | Invesco U.S. Small Cap Enhanced ETF | 0.06% |
Weight is the stock’s share of each fund’s holdings.
